|
1
|
Esiashvili N, Goodman M and Marcus RB Jr:
Changes in incidence and survival of Ewing sarcoma patients over
the past 3 decades-surveillance epidemiology and end results data.
J Pediatr Hematol Oncol. 30:425–430. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Galyfos G, Karantzikos GA, Kavouras N,
Sianou A, Palogos K and Filis K: Extraosseous ewing sarcoma:
Diagnosis, prognosis and optimal management. Indian J Surg.
78:49–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Max D, Kuehnoel CD, Burdach S, Niu L,
Staege MS and Foell JL: Indoleamine-2,3-dioxygenase in an
immunotherapy model for ewing sarcoma. Anticancer Res.
34:6431–6441. 2014.PubMed/NCBI
|
|
4
|
Ladenstein R, Poetschger U, Le Deley MC,
Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth
L, Michon J, et al: Primary Disseminated Multifocal Ewing Sarcoma:
Results of the Euro-EWING 99 Trial. J Clin Oncol. 28:3284–3291.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sand LG, Szuhai K and Hogendoorn PC:
Sequencing Overview of ewing sarcoma: A journey across genomic,
epigenomic and transcriptomic landscapes. Int J Mol Sci.
16:16176–16215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen D, Li Z, Yang Q, Zhang J, Zhai Z and
Shu HB: Identification of a nuclear protein that promotes NF-kappaB
activation. Biochem Biophys Res Commun. 310:720–724. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burgute BD, Peche VS, Steckelberg AL,
Glöckner G, Gaßen B, Gehring NH and Noegel AA: NKAP is a novel
RS-related protein that interacts with RNA and RNA binding
proteins. Nucleic Acids Res. 42:3177–3193. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thapa P, Chen MW, McWilliams DC, Belmonte
P, Constans M, Sant'Angelo DB and Shapiro VS: NKAP Regulates
Invariant NKT Cell Proliferation and Differentiation into
ROR-gammat-Expressing NKT17 Cells. J Immunol. 196:4987–4998. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pajerowski AG, Nguyen C, Aghajanian H,
Shapiro MJ and Shapiro VS: NKAP is a transcriptional repressor of
notch signaling and is required for T cell development. Immunity.
30:696–707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thapa P, Das J, McWilliams D, Shapiro M,
Sundsbak R, Nelson-Holte M, Tangen S, Anderson J, Desiderio S,
Hiebert S, et al: The transcriptional repressor NKAP is required
for the development of iNKT cells. Nat Commun. 4:15822013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu FC, Pajerowski AG, Nelson-Holte M,
Sundsbak R and Shapiro VS: NKAP is required for T cell maturation
and acquisition of functional competency. J Exp Med. 208:1291–1304.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dash B, Shapiro MJ, Chung JY, Romero
Arocha S and Shapiro VS: Treg-specific deletion of NKAP results in
severe, systemic autoimmunity due to peripheral loss of Tregs. J
Autoimmun. 89:139–148. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Worlitzer MM and Schwamborn JC: The Notch
co-repressor protein NKAP is highly expressed in adult mouse
subventricular zone neural progenitor cells. Neuroscience.
266:138–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pajerowski AG, Shapiro MJ, Gwin K,
Sundsbak R, Nelson-Holte M, Medina K and Shapiro VS: Adult
hematopoietic stem cells require NKAP for maintenance and survival.
Blood. 116:2684–2693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li T, Chen L, Cheng J, Dai J, Huang Y,
Zhang J, Liu Z, Li A, Li N, Wang H, et al: SUMOylated NKAP is
essential for chromosome alignment by anchoring CENP-E to
kinetochores. Nat Commun. 7:129692016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Wang H, Yin Y, Li Q and Zhang M:
NKAP functions as an oncogene and its expression is induced by
CoCl2 treatment in breast cancer via AKT/mTOR signaling pathway.
Cancer Manag Res. 10:5091–5100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/Akt and apoptosis: Size matters. Oncogene.
22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lassen A, Atefi M, Robert L, Wong DJ,
Cerniglia M, Comin-Anduix B and Ribas A: Effects of AKT inhibitor
therapy in response and resistance to BRAF inhibition in melanoma.
Mol Cancer. 13:832014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi BD, Jeong SJ, Wang G, Park JJ, Lim
DS, Kim BH, Cho YI, Kim CS and Jeong MJ: Secretory leukocyte
protease inhibitor is associated with MMP-2 and MMP-9 to promote
migration and invasion in SNU638 gastric cancer cells. Int J Mol
Med. 28:527–534. 2011.PubMed/NCBI
|
|
22
|
Zhang X, Min J, Wang Y, Li Y and Li H, Liu
Q, Liang X, Mu P and Li H: RABEX-5 plays an oncogenic role in
breast cancer by activating MMP-9 pathway. J Exp Clin Cancer Res.
32:522013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gui D, Guo Y, Wang F, Liu W, Chen J, Chen
Y, Huang J and Wang N: Astragaloside IV, a novel antioxidant,
prevents glucose-induced podocyte apoptosis in vitro and in vivo.
PLoS One. 7:e398242012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:922011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang TQ, Lu XJ, Wu TF, Ding DD, Zhao ZH,
Chen GL, Xie XS, Li B, Wei YX, Guo LC, et al: MicroRNA-16 inhibits
glioma cell growth and invasion through suppression of BCL2 and the
nuclear factor-kappaB1/MMP-9 signaling pathway. Cancer Sci.
105:265–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Radha G and Raghavan SC: BCL2: A promising
cancer therapeutic target. Biochim Biophys Acta Rev Cancer.
1868:309–314. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
